---
title: "FIRE-3"
slug: "fire"
date: "2023-09-21"
enableToc: false
tags:
  - building
---

> [!info]
>
> 🌱 來自: [[Metastatic Colon Cancer]]

# FIRE-3

- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
- `28.7 months` (95% CI 24·0-36·6) in the cetuximab group compared with 25.0 months (22·7-27·6) in the bevacizumab group
